Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The Titan CD8-guiding technology seems to have spawned a new variant.
The first pivotal data with raludotatug deruxtecan will feature as a late-breaker.
A Chinese phase 3 of the biparatopic DLL3 T-cell engager alveltamig will start soon.
A single-arm trial was enough for J&J’s Inlexzo nod.
The Kandlelit-007 trial will assess MK-1084 plus SC Keytruda across PD-L1 expression levels.
ESMO and the Triple Meeting approach.
